<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01744704</url>
  </required_header>
  <id_info>
    <org_study_id>NGF0112</org_study_id>
    <secondary_id>2012-004302-10</secondary_id>
    <nct_id>NCT01744704</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers</brief_title>
  <acronym>NGF0112</acronym>
  <official_title>Phase I, Randomised, Double-masked, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dompé Farmaceutici S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dompé Farmaceutici S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerability of single and
      multiple ascending doses of rhNGF when administered as eye drops in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, randomised, double-masked, placebo-controlled eye drops administration
      study of rh-NGF in healthy male and female subjects.

      This study consists of a single ascending dose part (part 0 one drop single application).
      Then single ascending dose part (part A; one drop three times a day) and a multiple ascending
      dose part (part B; one drop three times a day for five days). All parts of the study will
      consist of 3 ascending dose levels.

      In order to support the dose escalation MAD phase from Covance, Basel to Covance, Leeds, an
      additional cohort (0M) will be conducted at Covance, Leeds at the same dose level as cohort
      1M to ensure a degree of consistency between the two sites, i.e. that no dose escalation
      stopping criteria were met at either site.

      In Part 0, each ascending dose cohort will include 3 subjects treated with one dose of
      rh-NGF.

      In part A, each ascending dose cohort will include 6 subjects treated with rh-NGF and 2 with
      placebo.

      In part B, each ascending dose cohort will include 9 subjects treated with rh-NGF drug and 3
      with placebo, in addition to cohort 0M, which will include 3 subjects treated with rh-NGF and
      1 with placebo
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in VAS Ocular Tolerability</measure>
    <time_frame>Day -1, Day 1, Day 5, Day 15 (FU)</time_frame>
    <description>A global ocular discomfort score was determined using a 100 mm visual analogue scale (VAS) on which 0 means no symptoms and 100 means the worst possible discomfort. This evaluation was performed before any ophthalmic assessment at a given study visit. Specific ocular symptoms to be assessed with the VAS included: foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision, photophobia.
Part 0: VAS evaluated on days -1, 1, 3, 10 (FU) Part A: VAS evaluated on days -1, 1, 3, 10 (FU) Part B: VAS evaluated on days -1, 1, 5, 15 (FU) Follow up (FU) refers to participants' last available assessment.
The Outcome Measure Time Points and Data Table refers to Part B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Best Corrected Distance Visual Acuity (BCDVA)</measure>
    <time_frame>Day -1, Day 1, Day 5, Day 15 (FU)</time_frame>
    <description>Best corrected distance visual acuity measured using the ETDRS (Early Treatment Diabetic Retinopathy Study) score. In this population, the scores range from -6 (worse visus) to 3 (best visus).
The study includes Part 0, Part A and Part B. In Part B BCDVA was evaluated on days -1, 1, 5, 15 (FU). Follow up (FU) refers to participants' last available assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Mean Tear Film Break up Time (TFBUT)</measure>
    <time_frame>Day -1, Day 1, Day 5, Day 15 (FU)</time_frame>
    <description>Tear film break-up time was assessed by slit lamp examination (SLE). The shorter is the tear film break-up time, the worse is the dry eye symptom severity.
The study includes Part 0, Part A and Part B. In Part B this endpoint was evaluated on days -1, 1, 5, 15 (FU). Follow up (FU) refers to participants' last available assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Mean Corneal Fluorescein Staining</measure>
    <time_frame>Day -1, Day 1, Day 5, Day 15 (FU)</time_frame>
    <description>Slit lamp examination was used to assess the eyelid margin, conjunctiva, cornea, anterior chamber, iris and lens with the instillation of fluorescein to evaluate corneal fluorescein staining (modified Oxford scale).
This is 7-point ordinal scale that scores 0, 0.5, and 1 to 5. On this scale the score 0 corresponds to no staining dots (complete corneal clearing) and the score 0.5 corresponds to three or less staining dots. The higher is the number of dots, the higher and worse is the score.
The study includes Part 0, Part A and Part B. In Part B the endpoint was evaluated on days -1, 1, 5, 15 (FU).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Intraocular Pressure (IOP)</measure>
    <time_frame>Screening, Day 7, Day 15 (FU)</time_frame>
    <description>Intraocular pressure was determined using Goldmann applanation tonometry. The study includes Part 0, Part A and Part B. In Part B this endpoint was evaluated at screening and on days 7, 15 (FU).
Follow up (FU) refers to participants' last available assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Abnormal Findings in Dilated Fundus Ophthalmoscopy</measure>
    <time_frame>Part B - Day 7</time_frame>
    <description>Dilated fundus ophthalmoscopy (DFO) is used to view the eye's interior, allowing assessment of the retina/macula/choroid, optic nerve head, blood vessels, and other features.
The outcome can be normal or abnormal. The study includes Part 0, Part A and Part B. In Part B this endpoint was evaluated on day 7.</description>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>rhNGF 0.5 µg/mL Sentinel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x 35 µL drop 3 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNGF 5 µg/mL Sentinel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x 35 µL drop 3 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNGF 60 µg/mL Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 x 35 µL drops applied at 4 h intervals 6 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNGF 20 µg/mL Sentinel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 x 35 µL drop 3 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNGF 20 µg/mL Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 x 35 µL drops applied at 4 h intervals 6 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNGF 180 µg/mL Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 x 35 µL drops applied at 4 h intervals 6 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 x 35 µL drops applied at 4 h intervals 6 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNGF 20 µg/mL Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 12 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNGF 60 µg/mL Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhNGF 180 µg/mL Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 0.5 µg/mL Sentinel</intervention_name>
    <description>In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level</description>
    <arm_group_label>rhNGF 0.5 µg/mL Sentinel</arm_group_label>
    <other_name>Recombinant Human Nerve Growth Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 5 µg/mL Sentinel</intervention_name>
    <description>Part 0 represented a sentinel group.</description>
    <arm_group_label>rhNGF 5 µg/mL Sentinel</arm_group_label>
    <other_name>Recombinant Human Nerve Growth Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 20 µg/mL Sentinel</intervention_name>
    <description>In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level</description>
    <arm_group_label>rhNGF 20 µg/mL Sentinel</arm_group_label>
    <other_name>Recombinant Human Nerve Growth Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 20 µg/mL Part A</intervention_name>
    <description>In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.</description>
    <arm_group_label>rhNGF 20 µg/mL Part A</arm_group_label>
    <other_name>Recombinant Human Nerve Growth Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 60 µg/mL Part A</intervention_name>
    <description>In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.</description>
    <arm_group_label>rhNGF 60 µg/mL Part A</arm_group_label>
    <other_name>Recombinant Human Nerve Growth Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 180 µg/mL Part A</intervention_name>
    <description>In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.</description>
    <arm_group_label>rhNGF 180 µg/mL Part A</arm_group_label>
    <other_name>Recombinant Human Nerve Growth Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 20 µg/mL Part B</intervention_name>
    <description>In Part B, as planned 3 dose levels of rh-NGF or placebo eye drops were studied in a total of 40 healthy subjects.</description>
    <arm_group_label>rhNGF 20 µg/mL Part B</arm_group_label>
    <other_name>Recombinant Human Nerve Growth Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 60 µg/mL Part B</intervention_name>
    <description>In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.</description>
    <arm_group_label>rhNGF 60 µg/mL Part B</arm_group_label>
    <other_name>Recombinant Human Nerve Growth Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhNGF 180 µg/mL Part B</intervention_name>
    <description>In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.</description>
    <arm_group_label>rhNGF 180 µg/mL Part B</arm_group_label>
    <other_name>Recombinant Human Nerve Growth Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Part A</intervention_name>
    <description>In Part A, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h on Day 1 to achieve the required fractionated single dose level.</description>
    <arm_group_label>Placebo Part A</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Part B</intervention_name>
    <description>In Part B, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration or placebo in their study eye (right or left) according to the randomisation list (and 1 drop of placebo in the non-study eye). This occurred q4h for 5 days to achieve the required multiple fractionated dose level.</description>
    <arm_group_label>Placebo Part B</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects, aged between 18 and 60 years, inclusive.

          -  Subject has to be able to communicate well with the investigator, understands and
             complies with the requirements of the study, and understands and signs the written
             volunteer informed consent form.

          -  Subject's systemic and ocular medical history must be considered normal in the opinion
             of the investigator at the Screening and Baseline visits.

          -  Best corrected distance visual acuity (BCDVA) score ≤ 0.00 LogMAR (≥83 ETDRS letters,
             20/20 Snellen or 1.0 decimal fraction) in each eye at the Screening and Baseline
             visits.

          -  Normal anterior segment on external and slit lamp examination in both eyes at the
             Screening and Baseline visits.

          -  Normal posterior segment on fundus ophthalmoscopic examination in both eyes at the
             Screening and Baseline visits.

          -  Subject must be considered in good systemic health in the opinion of the investigator
             at the Screening and Baseline visits, as determined by:

               1. Subject's body mass index is between 18.5 and 30.4 kg/m2 inclusive

               2. A pre-study physical examination with no clinically significant abnormalities.

               3. Vital signs within clinically acceptable ranges for the purposes of the study
                  (sitting systolic blood pressure [BP] ≥ 90 mmHg and ≤ 150 mmHg; diastolic BP ≥ 50
                  mmHg and ≤ 95 mmHg; heart rate (pulse rate) ≥ 40 and ≤ 100 beats per minute; oral
                  body temperature ≥ 35.5°C and ≤ 37.5°C).

               4. An ECG with no clinically significant abnormalities, in the opinion of the
                  Investigator.

               5. Pre-study clinical laboratory findings within normal range or not deemed
                  clinically significant in the opinion of the investigator if outside of the
                  normal range

          -  Female subjects will be:

               -  either post menopausal where post menopause is defined as the period following
                  peri-menopause, i.e. postmenopausal after 12 months without a menstrual period
                  and with a serum FSH value within the reference range for postmenopausal females
                  at Screening

               -  or permanently sterilised (e.g. tubal occlusion, hysterectomy, bilateral
                  salpingectomy)

               -  or be using 2 different forms of highly effective contraception throughout the
                  study.

        Male subjects with female partners of child-bearing potential must use 2 different forms of
        highly effective contraception throughout the study and for a further 3 months after the
        follow-up visit and all male subjects must be willing to avoid donating sperm during this
        time.

        Exclusion Criteria:

          -  Subject has had a clinically significant illness in the 6 weeks before screening in
             the opinion of the investigator.

          -  Subject is not suitable to participate in the study in the opinion of the investigator

          -  Subject has participated in any clinical study with an investigational drug/device
             within 3 months prior to the first day of dosing.

          -  Subject has had a serious adverse reaction or significant hypersensitivity to any drug
             or chemically related compounds or has a clinically significant allergy to drugs,
             foods or other materials (in the opinion of the investigator).

          -  Administration of any topical ocular (prescription or over the counter including
             artificial tears) or systemic medication including herbal product or fish oil
             preparations within 14 days before the first dose of study drug. Vitamins and mineral
             supplements not containing other substances are allowed until 96 hours before each
             dose if considered by the Investigator unlikely to interfere with the study results.
             Paracetamol at doses of at most 2 grams per day and ibuprofen at doses of at most 1200
             mg per day for no more than 3 consecutive days or 6 non-consecutive days are allowed.
             Oral, injectable and implantable hormonal contraceptives are allowed without
             restrictions for female subjects. Longer exclusion periods apply for:

               1. amiodarone and hydroxychloroquine (210 days),

               2. monoclonal antibodies/ immunoglobulins/ other therapeutic proteins (120 days)

               3. Experimental drugs with a half life known to the Study Unit: Five half lives plus
                  2 weeks

               4. Experimental drugs with a half life unknown to the Study Unit: 120 days

               5. chloroquine and flunarizine (100 days)

               6. fluoxetine (75 days),

               7. benzodiazepines different from midazolam, lorazepam and triazolam,
                  chlorpromazine, mephenytoin, nortryptyline, phenobarbital, primidone,
                  carbamazepine, phenytoin and phenprocoumon (35 days).

          -  Subject has a significant history of drug/solvent abuse (within the last 2 years) or a
             positive drugs of abuse test at any time during the study.

          -  Subject has a history of alcohol abuse (within the last 2 years) or currently drinks
             in excess of 28 units per week or has a positive alcohol breath test at any time
             during the study.

          -  Subject is a smoker or has smoked in the 6 months prior to dosing.

          -  Subject who has a positive human immunodeficiency virus (HIV) screen, hepatitis B
             screen or hepatitis C screen.

          -  Subject has donated blood or blood products (e.g., plasma or platelets) within the 3
             months prior to screening.

          -  Subject has a partner who will be pregnant or breastfeeding during the study

          -  Pregnant or breastfeeding female or those with a positive pregnancy test or who will
             not use a medically acceptable contraceptive method from selection and during the
             study

          -  Subject having used any glucocorticosteroid by any route in the last 30 days whichever
             the route of administration, or any medication by ocular or nasal administration route
             from 30 days before screening.

          -  Subjects currently diagnosed with any active ocular disease, even if mild, other than
             refractive error.

          -  Subject with history of ocular surgery, including laser refractive surgery

          -  Subject using a contact lens within 7 days prior administration of the first dose

          -  Intraocular pressure (IOP) &gt;= 22 mmHg in either eye

          -  Presence of any corneal opacity or corneal fluorescein staining &gt;0.5 grade using the
             modified Oxford scale

          -  Schirmer's test without anesthesia &lt;= 9 mm/5 minutes

          -  Tear film break up time &lt; 8 seconds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Kamtchoua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Basel Research Unit AG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashley Brooks, MBChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pier Adelchi Ruffini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dompé s.p.a.Via San Martino, 12 - 20122 Milan, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauro P Ferrari, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Dompé s.p.a. - Via San Martino, 12 - 20122 Milan, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Basel Research Unit AG - Lettenweg 118 -</name>
      <address>
        <city>Allschwil</city>
        <zip>CH - 4123</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COVANCE CLINICAL RESEARCH UNIT Ltd - Springfield House - Hyde Street</name>
      <address>
        <city>Leeds</city>
        <zip>LS2 9LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology. 1998 Sep;51(3):695-702.</citation>
    <PMID>9748012</PMID>
  </reference>
  <reference>
    <citation>Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Giuliani M, Stevens JC, Barbano R, Dyck PJ. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. JAMA. 2000 Nov 1;284(17):2215-21.</citation>
    <PMID>11056593</PMID>
  </reference>
  <reference>
    <citation>Bonini S, Lambiase A, Rama P, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmology. 2000 Jul;107(7):1347-51; discussion 1351-2.</citation>
    <PMID>10889110</PMID>
  </reference>
  <reference>
    <citation>Lambiase A, Rama P, Bonini S, Caprioglio G, Aloe L. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998 Apr 23;338(17):1174-80.</citation>
    <PMID>9554857</PMID>
  </reference>
  <reference>
    <citation>Liu Q, McDermott AM, Miller WL. Elevated nerve growth factor in dry eye associated with established contact lens wear. Eye Contact Lens. 2009 Sep;35(5):232-7. doi: 10.1097/ICL.0b013e3181b3e87f.</citation>
    <PMID>19672199</PMID>
  </reference>
  <reference>
    <citation>Petty BG, Cornblath DR, Adornato BT, Chaudhry V, Flexner C, Wachsman M, Sinicropi D, Burton LE, Peroutka SJ. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol. 1994 Aug;36(2):244-6.</citation>
    <PMID>8053664</PMID>
  </reference>
  <reference>
    <citation>Qi H, Li DQ, Shine HD, Chen Z, Yoon KC, Jones DB, Pflugfelder SC. Nerve growth factor and its receptor TrkA serve as potential markers for human corneal epithelial progenitor cells. Exp Eye Res. 2008 Jan;86(1):34-40. Epub 2007 Sep 15.</citation>
    <PMID>17980361</PMID>
  </reference>
  <reference>
    <citation>Schifitto G, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra CM, Rubin M, Cohen BA, Tucker T, Koralnik IJ, Katzenstein D, Haidich B, Smith ME, Shriver S, Millar L, Clifford DB, McArthur JC; AIDS Clinical Trials Group Team 291. Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy. Neurology. 2001 Oct 9;57(7):1313-6.</citation>
    <PMID>11591856</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 5, 2012</study_first_submitted>
  <study_first_submitted_qc>December 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2012</study_first_posted>
  <results_first_submitted>August 26, 2014</results_first_submitted>
  <results_first_submitted_qc>July 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2019</results_first_posted>
  <last_update_submitted>July 30, 2019</last_update_submitted>
  <last_update_submitted_qc>July 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nerve Growth Factor</keyword>
  <keyword>Ophthalmic Solutions</keyword>
  <keyword>Eye Drops</keyword>
  <keyword>rh-NGF</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>rhNGF 0.5 µg/mL Sentinel</title>
          <description>1 x 35 µL drop 3 subjects
rhNGF 0.5 µg/mL Sentinel: one drop administration</description>
        </group>
        <group group_id="P2">
          <title>rhNGF 5 µg/mL Sentinel</title>
          <description>1 x 35 µL drop 3 subjects
rhNGF 5 µg/mL Sentinel</description>
        </group>
        <group group_id="P3">
          <title>rhNGF 20 µg/mL Sentinel</title>
          <description>1 x 35 µL drop 3 subjects
rhNGF 20 µg/mL Sentinel</description>
        </group>
        <group group_id="P4">
          <title>rhNGF 60 µg/mL Part A</title>
          <description>3 x 35 µL drops applied at 4 h intervals 6 subjects
rhNGF 60 µg/mL Part A</description>
        </group>
        <group group_id="P5">
          <title>rhNGF 20 µg/mL Part A</title>
          <description>3 x 35 µL drops applied at 4 h intervals 6 subjects
rhNGF 20 µg/mL Part A</description>
        </group>
        <group group_id="P6">
          <title>rhNGF 180 µg/mL Part A</title>
          <description>3 x 35 µL drops applied at 4 h intervals 6 subjects
rhNGF 180 µg/mL Part A</description>
        </group>
        <group group_id="P7">
          <title>Placebo Part A</title>
          <description>3 x 35 µL drops applied at 4 h intervals 6 subjects
Placebo Part A</description>
        </group>
        <group group_id="P8">
          <title>rhNGF 20 µg/mL Part B</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subject
rhNGF 20 µg/mL Part B</description>
        </group>
        <group group_id="P9">
          <title>rhNGF 20 µg/mL Part B Cohort 0M</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 3 subjects
rhNGF 20 µg/mL Part B cohort 0M</description>
        </group>
        <group group_id="P10">
          <title>rhNGF 60 µg/mL Part B</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 60 µg/mL Part B</description>
        </group>
        <group group_id="P11">
          <title>rhNGF 180 µg/mL Part B</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 180 µg/mL Part B</description>
        </group>
        <group group_id="P12">
          <title>Placebo Part B</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
Placebo Part B</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="7"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="9"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="9"/>
                <participants group_id="P12" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>rhNGF 0.5 µg/mL Sentinel</title>
          <description>1 x 35 µL drop 3 subjects
rhNGF 0.5 µg/mL Sentinel: one drop administration</description>
        </group>
        <group group_id="B2">
          <title>rhNGF 5 µg/mL Sentinel</title>
          <description>1 x 35 µL drop 3 subjects
rhNGF 5 µg/mL Sentinel</description>
        </group>
        <group group_id="B3">
          <title>rhNGF 20 µg/mL Sentinel</title>
          <description>1 x 35 µL drop 3 subjects
rhNGF 20 µg/mL Sentinel</description>
        </group>
        <group group_id="B4">
          <title>rhNGF 20 µg/mL Part A</title>
          <description>3 x 35 µL drops applied at 4 h intervals 6 subjects
rhNGF 20 µg/mL Part A</description>
        </group>
        <group group_id="B5">
          <title>rhNGF 60 µg/mL Part A</title>
          <description>3 x 35 µL drops applied at 4 h intervals 6 subjects
rhNGF 60 µg/mL Part A</description>
        </group>
        <group group_id="B6">
          <title>rhNGF 180 µg/mL Part A</title>
          <description>3 x 35 µL drops applied at 4 h intervals 6 subjects
rhNGF 180 µg/mL Part A</description>
        </group>
        <group group_id="B7">
          <title>Placebo Part A</title>
          <description>3 x 35 µL drops applied at 4 h intervals 6 subjects
Placebo Part A</description>
        </group>
        <group group_id="B8">
          <title>rhNGF 20 µg/mL Part B</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subject
rhNGF 20 µg/mL Part B</description>
        </group>
        <group group_id="B9">
          <title>rhNGF 60 µg/mL Part B</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 60 µg/mL Part B</description>
        </group>
        <group group_id="B10">
          <title>rhNGF 180 µg/mL Part B</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 180 µg/mL Part B</description>
        </group>
        <group group_id="B11">
          <title>Placebo Part B</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
Placebo Part B</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="7"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="12"/>
            <count group_id="B9" value="9"/>
            <count group_id="B10" value="9"/>
            <count group_id="B11" value="10"/>
            <count group_id="B12" value="74"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="7"/>
                    <measurement group_id="B2" value="47" spread="9.2"/>
                    <measurement group_id="B3" value="29" spread="11.9"/>
                    <measurement group_id="B4" value="46" spread="10"/>
                    <measurement group_id="B5" value="36" spread="9.4"/>
                    <measurement group_id="B6" value="42" spread="17.8"/>
                    <measurement group_id="B7" value="42" spread="9"/>
                    <measurement group_id="B8" value="41" spread="12.1"/>
                    <measurement group_id="B9" value="36" spread="14.7"/>
                    <measurement group_id="B10" value="29" spread="10.3"/>
                    <measurement group_id="B11" value="36" spread="12.6"/>
                    <measurement group_id="B12" value="40.2" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="9"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in VAS Ocular Tolerability</title>
        <description>A global ocular discomfort score was determined using a 100 mm visual analogue scale (VAS) on which 0 means no symptoms and 100 means the worst possible discomfort. This evaluation was performed before any ophthalmic assessment at a given study visit. Specific ocular symptoms to be assessed with the VAS included: foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision, photophobia.
Part 0: VAS evaluated on days -1, 1, 3, 10 (FU) Part A: VAS evaluated on days -1, 1, 3, 10 (FU) Part B: VAS evaluated on days -1, 1, 5, 15 (FU) Follow up (FU) refers to participants' last available assessment.
The Outcome Measure Time Points and Data Table refers to Part B.</description>
        <time_frame>Day -1, Day 1, Day 5, Day 15 (FU)</time_frame>
        <population>Safety population: consisted of all subjects randomised into the study and receiving a dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>rhNGF 0.5 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 0.5 µg/mL Sentinel: one drop administration</description>
          </group>
          <group group_id="O2">
            <title>rhNGF 5 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 5 µg/mL Sentinel</description>
          </group>
          <group group_id="O3">
            <title>rhNGF 20 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 20 µg/mL Sentinel</description>
          </group>
          <group group_id="O4">
            <title>rhNGF 20 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 20 µg/mL Part A</description>
          </group>
          <group group_id="O5">
            <title>rhNGF 60 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 60 µg/mL Part A</description>
          </group>
          <group group_id="O6">
            <title>rhNGF 180 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 180 µg/mL Part A</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects Placebo Part A</description>
          </group>
          <group group_id="O8">
            <title>rhNGF 20 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subject
rhNGF 20 µg/mL Part B</description>
          </group>
          <group group_id="O9">
            <title>rhNGF 60 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 60 µg/mL Part B</description>
          </group>
          <group group_id="O10">
            <title>rhNGF 180 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 180 µg/mL Part B</description>
          </group>
          <group group_id="O11">
            <title>Placebo Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
Placebo Part B</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in VAS Ocular Tolerability</title>
          <description>A global ocular discomfort score was determined using a 100 mm visual analogue scale (VAS) on which 0 means no symptoms and 100 means the worst possible discomfort. This evaluation was performed before any ophthalmic assessment at a given study visit. Specific ocular symptoms to be assessed with the VAS included: foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision, photophobia.
Part 0: VAS evaluated on days -1, 1, 3, 10 (FU) Part A: VAS evaluated on days -1, 1, 3, 10 (FU) Part B: VAS evaluated on days -1, 1, 5, 15 (FU) Follow up (FU) refers to participants' last available assessment.
The Outcome Measure Time Points and Data Table refers to Part B.</description>
          <population>Safety population: consisted of all subjects randomised into the study and receiving a dose of study medication.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Foreign body sensation - Day 1 (8h) vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="3" spread="7.3"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0.4" spread="0"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                    <measurement group_id="O9" value="0" spread="0.5"/>
                    <measurement group_id="O10" value="0" spread="0.5"/>
                    <measurement group_id="O11" value="0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Foreign body sensation - Day 5 vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="1" spread="2.6"/>
                    <measurement group_id="O9" value="0" spread="0.5"/>
                    <measurement group_id="O10" value="0" spread="0.7"/>
                    <measurement group_id="O11" value="0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Foreign body sensation - FU vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0.6"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                    <measurement group_id="O9" value="0" spread="0.5"/>
                    <measurement group_id="O10" value="0" spread="0.4"/>
                    <measurement group_id="O11" value="0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning/Stinging - Day 1 (8h) vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0.6"/>
                    <measurement group_id="O4" value="2" spread="4.9"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="0" spread="0.3"/>
                    <measurement group_id="O9" value="0" spread="0.5"/>
                    <measurement group_id="O10" value="0" spread="0.6"/>
                    <measurement group_id="O11" value="0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning/Stinging - Day 5 vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="1" spread="3.5"/>
                    <measurement group_id="O9" value="0" spread="0.4"/>
                    <measurement group_id="O10" value="0" spread="0.5"/>
                    <measurement group_id="O11" value="0" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning/Stinging - FU vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="0" spread="0.3"/>
                    <measurement group_id="O9" value="0" spread="0.5"/>
                    <measurement group_id="O10" value="0" spread="0.4"/>
                    <measurement group_id="O11" value="0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching - Day 1 (8h) vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0.4"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0.4"/>
                    <measurement group_id="O8" value="0" spread="0.3"/>
                    <measurement group_id="O9" value="0" spread="0.3"/>
                    <measurement group_id="O10" value="0" spread="0.7"/>
                    <measurement group_id="O11" value="0" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching - Day 5 vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0.6"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0.4"/>
                    <measurement group_id="O8" value="0" spread="0.3"/>
                    <measurement group_id="O9" value="0" spread="0.3"/>
                    <measurement group_id="O10" value="0" spread="0.4"/>
                    <measurement group_id="O11" value="0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching - FU vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="0" spread="0.3"/>
                    <measurement group_id="O9" value="0" spread="0.7"/>
                    <measurement group_id="O10" value="0" spread="0.6"/>
                    <measurement group_id="O11" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Day 1 (8h) vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0.4"/>
                    <measurement group_id="O8" value="0" spread="0.3"/>
                    <measurement group_id="O9" value="0" spread="0.7"/>
                    <measurement group_id="O10" value="0" spread="0.7"/>
                    <measurement group_id="O11" value="0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - Day 5 vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0.4"/>
                    <measurement group_id="O8" value="0" spread="0.3"/>
                    <measurement group_id="O9" value="1" spread="3.5"/>
                    <measurement group_id="O10" value="4" spread="6.5"/>
                    <measurement group_id="O11" value="0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain - FU vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.2"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0.4"/>
                    <measurement group_id="O8" value="0" spread="0.3"/>
                    <measurement group_id="O9" value="0" spread="0.7"/>
                    <measurement group_id="O10" value="0" spread="0.4"/>
                    <measurement group_id="O11" value="0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sticky feeling - Day 1 (8h) vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.7"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="-3" spread="4.6"/>
                    <measurement group_id="O4" value="-1" spread="1.6"/>
                    <measurement group_id="O5" value="0" spread="0.8"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="1" spread="2.4"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                    <measurement group_id="O9" value="0" spread="0.7"/>
                    <measurement group_id="O10" value="3" spread="7.6"/>
                    <measurement group_id="O11" value="0" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sticky feeling - Day 5 vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.7"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="-2" spread="4.9"/>
                    <measurement group_id="O4" value="-1" spread="1.6"/>
                    <measurement group_id="O5" value="0" spread="0.8"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0.4"/>
                    <measurement group_id="O8" value="0" spread="0.3"/>
                    <measurement group_id="O9" value="0" spread="0.5"/>
                    <measurement group_id="O10" value="1" spread="3.6"/>
                    <measurement group_id="O11" value="0" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sticky feeling - FU vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.7"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="-3" spread="4.6"/>
                    <measurement group_id="O4" value="-1" spread="1.6"/>
                    <measurement group_id="O5" value="0" spread="0.8"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0.4"/>
                    <measurement group_id="O8" value="0" spread="0.3"/>
                    <measurement group_id="O9" value="0" spread="0.5"/>
                    <measurement group_id="O10" value="0" spread="0.4"/>
                    <measurement group_id="O11" value="0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blurred vision - Day 1 (8h) vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="1.5"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0.4"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                    <measurement group_id="O9" value="0" spread="0.5"/>
                    <measurement group_id="O10" value="0" spread="0.3"/>
                    <measurement group_id="O11" value="0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blurred vision - Day 5 vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="1.5"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                    <measurement group_id="O9" value="0" spread="0"/>
                    <measurement group_id="O10" value="0" spread="0.3"/>
                    <measurement group_id="O11" value="0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blurred vision - FU vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="1.5"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0.6"/>
                    <measurement group_id="O4" value="0" spread="0.4"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0.4"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                    <measurement group_id="O9" value="0" spread="0.3"/>
                    <measurement group_id="O10" value="1" spread="0.5"/>
                    <measurement group_id="O11" value="0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Photophobia - Day 1 (8h) vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.7"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="1" spread="3.3"/>
                    <measurement group_id="O5" value="1" spread="1.6"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                    <measurement group_id="O9" value="0" spread="0.5"/>
                    <measurement group_id="O10" value="0" spread="0.6"/>
                    <measurement group_id="O11" value="0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Photophobia - Day 5 vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.7"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0.6"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0.8"/>
                    <measurement group_id="O8" value="1" spread="2.0"/>
                    <measurement group_id="O9" value="0" spread="0.5"/>
                    <measurement group_id="O10" value="0" spread="0.7"/>
                    <measurement group_id="O11" value="0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Photophobia - FU vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="1.7"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0.8"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0.4"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                    <measurement group_id="O9" value="0" spread="0.7"/>
                    <measurement group_id="O10" value="0" spread="0.7"/>
                    <measurement group_id="O11" value="0" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Best Corrected Distance Visual Acuity (BCDVA)</title>
        <description>Best corrected distance visual acuity measured using the ETDRS (Early Treatment Diabetic Retinopathy Study) score. In this population, the scores range from -6 (worse visus) to 3 (best visus).
The study includes Part 0, Part A and Part B. In Part B BCDVA was evaluated on days -1, 1, 5, 15 (FU). Follow up (FU) refers to participants' last available assessment.</description>
        <time_frame>Day -1, Day 1, Day 5, Day 15 (FU)</time_frame>
        <population>Safety population consisted of all subjects randomised into the study and receiving a dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>rhNGF 0.5 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 0.5 µg/mL Sentinel: one drop administration</description>
          </group>
          <group group_id="O2">
            <title>rhNGF 5 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 5 µg/mL Sentinel</description>
          </group>
          <group group_id="O3">
            <title>rhNGF 20 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 20 µg/mL Sentinel</description>
          </group>
          <group group_id="O4">
            <title>rhNGF 20 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 20 µg/mL Part A</description>
          </group>
          <group group_id="O5">
            <title>rhNGF 60 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 60 µg/mL Part A</description>
          </group>
          <group group_id="O6">
            <title>rhNGF 180 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 180 µg/mL Part A</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects Placebo Part A</description>
          </group>
          <group group_id="O8">
            <title>rhNGF 20 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subject
rhNGF 20 µg/mL Part B</description>
          </group>
          <group group_id="O9">
            <title>rhNGF 60 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 60 µg/mL Part B</description>
          </group>
          <group group_id="O10">
            <title>rhNGF 180 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 180 µg/mL Part B</description>
          </group>
          <group group_id="O11">
            <title>Placebo Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
Placebo Part B</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Best Corrected Distance Visual Acuity (BCDVA)</title>
          <description>Best corrected distance visual acuity measured using the ETDRS (Early Treatment Diabetic Retinopathy Study) score. In this population, the scores range from -6 (worse visus) to 3 (best visus).
The study includes Part 0, Part A and Part B. In Part B BCDVA was evaluated on days -1, 1, 5, 15 (FU). Follow up (FU) refers to participants' last available assessment.</description>
          <population>Safety population consisted of all subjects randomised into the study and receiving a dose of study medication.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 vs Day-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0.6"/>
                    <measurement group_id="O2" value="3" spread="0.6"/>
                    <measurement group_id="O3" value="-6" spread="3.1"/>
                    <measurement group_id="O4" value="3" spread="1.6"/>
                    <measurement group_id="O5" value="0" spread="0.4"/>
                    <measurement group_id="O6" value="-0" spread="1.4"/>
                    <measurement group_id="O7" value="1" spread="1.6"/>
                    <measurement group_id="O8" value="1" spread="2.7"/>
                    <measurement group_id="O9" value="0" spread="3.7"/>
                    <measurement group_id="O10" value="0" spread="3.6"/>
                    <measurement group_id="O11" value="0" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 vs Day-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="2.3"/>
                    <measurement group_id="O2" value="0.0" spread="4.7"/>
                    <measurement group_id="O3" value="1" spread="2.1"/>
                    <measurement group_id="O4" value="1" spread="2.6"/>
                    <measurement group_id="O5" value="1" spread="2.5"/>
                    <measurement group_id="O6" value="0" spread="2.8"/>
                    <measurement group_id="O7" value="-1" spread="2.0"/>
                    <measurement group_id="O8" value="1" spread="2.7"/>
                    <measurement group_id="O9" value="1" spread="2.9"/>
                    <measurement group_id="O10" value="0" spread="3.3"/>
                    <measurement group_id="O11" value="0" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (FU) vs Day-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" spread="2.5"/>
                    <measurement group_id="O2" value="2" spread="1.0"/>
                    <measurement group_id="O3" value="-1" spread="2.9"/>
                    <measurement group_id="O4" value="2" spread="4.0"/>
                    <measurement group_id="O5" value="2" spread="1.9"/>
                    <measurement group_id="O6" value="0" spread="2.3"/>
                    <measurement group_id="O7" value="0" spread="3.2"/>
                    <measurement group_id="O8" value="1" spread="2.4"/>
                    <measurement group_id="O9" value="1" spread="2.4"/>
                    <measurement group_id="O10" value="2" spread="3.7"/>
                    <measurement group_id="O11" value="0" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Tear Film Break up Time (TFBUT)</title>
        <description>Tear film break-up time was assessed by slit lamp examination (SLE). The shorter is the tear film break-up time, the worse is the dry eye symptom severity.
The study includes Part 0, Part A and Part B. In Part B this endpoint was evaluated on days -1, 1, 5, 15 (FU). Follow up (FU) refers to participants' last available assessment.</description>
        <time_frame>Day -1, Day 1, Day 5, Day 15 (FU)</time_frame>
        <population>Safety population: consisted of all subjects randomised into the study and receiving a dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>rhNGF 0.5 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 0.5 µg/mL Sentinel: one drop administration</description>
          </group>
          <group group_id="O2">
            <title>rhNGF 5 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 5 µg/mL Sentinel</description>
          </group>
          <group group_id="O3">
            <title>rhNGF 20 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 20 µg/mL Sentinel</description>
          </group>
          <group group_id="O4">
            <title>rhNGF 20 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 20 µg/mL Part A</description>
          </group>
          <group group_id="O5">
            <title>rhNGF 60 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 60 µg/mL Part A</description>
          </group>
          <group group_id="O6">
            <title>rhNGF 180 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 180 µg/mL Part A</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects Placebo Part A</description>
          </group>
          <group group_id="O8">
            <title>rhNGF 20 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subject
rhNGF 20 µg/mL Part B</description>
          </group>
          <group group_id="O9">
            <title>rhNGF 60 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 60 µg/mL Part B</description>
          </group>
          <group group_id="O10">
            <title>rhNGF 180 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 180 µg/mL Part B</description>
          </group>
          <group group_id="O11">
            <title>Placebo Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
Placebo Part B</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Tear Film Break up Time (TFBUT)</title>
          <description>Tear film break-up time was assessed by slit lamp examination (SLE). The shorter is the tear film break-up time, the worse is the dry eye symptom severity.
The study includes Part 0, Part A and Part B. In Part B this endpoint was evaluated on days -1, 1, 5, 15 (FU). Follow up (FU) refers to participants' last available assessment.</description>
          <population>Safety population: consisted of all subjects randomised into the study and receiving a dose of study medication.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.89"/>
                    <measurement group_id="O2" value="0.0" spread="0.5"/>
                    <measurement group_id="O3" value="-2.6" spread="2.95"/>
                    <measurement group_id="O4" value="0.4" spread="0.86"/>
                    <measurement group_id="O5" value="-0.5" spread="0.64"/>
                    <measurement group_id="O6" value="-0.4" spread="1.93"/>
                    <measurement group_id="O7" value="0.0" spread="0.67"/>
                    <measurement group_id="O8" value="0.5" spread="1.14"/>
                    <measurement group_id="O9" value="0.4" spread="0.96"/>
                    <measurement group_id="O10" value="0.1" spread="1.11"/>
                    <measurement group_id="O11" value="0.2" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.62"/>
                    <measurement group_id="O2" value="-0.3" spread="1.04"/>
                    <measurement group_id="O3" value="0.9" spread="1.21"/>
                    <measurement group_id="O4" value="0.1" spread="0.69"/>
                    <measurement group_id="O5" value="-0.1" spread="0.85"/>
                    <measurement group_id="O6" value="0.0" spread="1.64"/>
                    <measurement group_id="O7" value="-0.7" spread="1.53"/>
                    <measurement group_id="O8" value="-0.2" spread="1.76"/>
                    <measurement group_id="O9" value="-0.4" spread="1.52"/>
                    <measurement group_id="O10" value="0.2" spread="2.03"/>
                    <measurement group_id="O11" value="-0.2" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (FU) vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.65"/>
                    <measurement group_id="O2" value="0.2" spread="0.29"/>
                    <measurement group_id="O3" value="-0.9" spread="1.4"/>
                    <measurement group_id="O4" value="-0.1" spread="1.32"/>
                    <measurement group_id="O5" value="0.4" spread="0.77"/>
                    <measurement group_id="O6" value="-0.6" spread="0.69"/>
                    <measurement group_id="O7" value="1.0" spread="1.22"/>
                    <measurement group_id="O8" value="0.1" spread="1.07"/>
                    <measurement group_id="O9" value="-0.4" spread="1.83"/>
                    <measurement group_id="O10" value="-0" spread="1.48"/>
                    <measurement group_id="O11" value="0.0" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Corneal Fluorescein Staining</title>
        <description>Slit lamp examination was used to assess the eyelid margin, conjunctiva, cornea, anterior chamber, iris and lens with the instillation of fluorescein to evaluate corneal fluorescein staining (modified Oxford scale).
This is 7-point ordinal scale that scores 0, 0.5, and 1 to 5. On this scale the score 0 corresponds to no staining dots (complete corneal clearing) and the score 0.5 corresponds to three or less staining dots. The higher is the number of dots, the higher and worse is the score.
The study includes Part 0, Part A and Part B. In Part B the endpoint was evaluated on days -1, 1, 5, 15 (FU).</description>
        <time_frame>Day -1, Day 1, Day 5, Day 15 (FU)</time_frame>
        <population>Safety population: consisted of all subjects randomised into the study and receiving a dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>rhNGF 0.5 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 0.5 µg/mL Sentinel: one drop administration</description>
          </group>
          <group group_id="O2">
            <title>rhNGF 5 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 5 µg/mL Sentinel</description>
          </group>
          <group group_id="O3">
            <title>rhNGF 20 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 20 µg/mL Sentinel</description>
          </group>
          <group group_id="O4">
            <title>rhNGF 20 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 20 µg/mL Part A</description>
          </group>
          <group group_id="O5">
            <title>hNGF 60 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 60 µg/mL Part A</description>
          </group>
          <group group_id="O6">
            <title>rhNGF 180 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 180 µg/mL Part A</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects Placebo Part A</description>
          </group>
          <group group_id="O8">
            <title>rhNGF 20 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subject
rhNGF 20 µg/mL Part B</description>
          </group>
          <group group_id="O9">
            <title>rhNGF 60 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 60 µg/mL Part B</description>
          </group>
          <group group_id="O10">
            <title>rhNGF 180 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 180 µg/mL Part B</description>
          </group>
          <group group_id="O11">
            <title>Placebo Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
Placebo Part B</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Corneal Fluorescein Staining</title>
          <description>Slit lamp examination was used to assess the eyelid margin, conjunctiva, cornea, anterior chamber, iris and lens with the instillation of fluorescein to evaluate corneal fluorescein staining (modified Oxford scale).
This is 7-point ordinal scale that scores 0, 0.5, and 1 to 5. On this scale the score 0 corresponds to no staining dots (complete corneal clearing) and the score 0.5 corresponds to three or less staining dots. The higher is the number of dots, the higher and worse is the score.
The study includes Part 0, Part A and Part B. In Part B the endpoint was evaluated on days -1, 1, 5, 15 (FU).</description>
          <population>Safety population: consisted of all subjects randomised into the study and receiving a dose of study medication.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.89"/>
                    <measurement group_id="O2" value="0.0" spread="0.50"/>
                    <measurement group_id="O3" value="-2.6" spread="2.95"/>
                    <measurement group_id="O4" value="0.4" spread="0.86"/>
                    <measurement group_id="O5" value="-0.5" spread="0.64"/>
                    <measurement group_id="O6" value="-0.4" spread="1.93"/>
                    <measurement group_id="O7" value="0.0" spread="0.67"/>
                    <measurement group_id="O8" value="0.2" spread="1.14"/>
                    <measurement group_id="O9" value="0.4" spread="0.96"/>
                    <measurement group_id="O10" value="0.1" spread="1.11"/>
                    <measurement group_id="O11" value="0.2" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.62"/>
                    <measurement group_id="O2" value="-0.3" spread="1.04"/>
                    <measurement group_id="O3" value="-0.9" spread="1.21"/>
                    <measurement group_id="O4" value="0.1" spread="0.69"/>
                    <measurement group_id="O5" value="-0.1" spread="0.85"/>
                    <measurement group_id="O6" value="0.0" spread="1.64"/>
                    <measurement group_id="O7" value="-0.7" spread="1.53"/>
                    <measurement group_id="O8" value="-0.2" spread="1.76"/>
                    <measurement group_id="O9" value="-0.4" spread="1.52"/>
                    <measurement group_id="O10" value="-0.2" spread="2.03"/>
                    <measurement group_id="O11" value="-0.2" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (FU) vs Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.65"/>
                    <measurement group_id="O2" value="0.2" spread="0.29"/>
                    <measurement group_id="O3" value="-0.9" spread="1.40"/>
                    <measurement group_id="O4" value="-0.1" spread="1.32"/>
                    <measurement group_id="O5" value="0.4" spread="0.77"/>
                    <measurement group_id="O6" value="-0.6" spread="0.69"/>
                    <measurement group_id="O7" value="1.0" spread="1.22"/>
                    <measurement group_id="O8" value="0.1" spread="1.07"/>
                    <measurement group_id="O9" value="-0.4" spread="1.83"/>
                    <measurement group_id="O10" value="-0.0" spread="1.48"/>
                    <measurement group_id="O11" value="0.0" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Intraocular Pressure (IOP)</title>
        <description>Intraocular pressure was determined using Goldmann applanation tonometry. The study includes Part 0, Part A and Part B. In Part B this endpoint was evaluated at screening and on days 7, 15 (FU).
Follow up (FU) refers to participants' last available assessment.</description>
        <time_frame>Screening, Day 7, Day 15 (FU)</time_frame>
        <population>Safety population: consisted of all subjects randomised into the study and receiving a dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>rhNGF 0.5 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 0.5 µg/mL Sentinel: one drop administration</description>
          </group>
          <group group_id="O2">
            <title>rhNGF 5 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 5 µg/mL Sentinel</description>
          </group>
          <group group_id="O3">
            <title>rhNGF 20 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 20 µg/mL Sentinel</description>
          </group>
          <group group_id="O4">
            <title>rhNGF 20 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 20 µg/mL Part A</description>
          </group>
          <group group_id="O5">
            <title>rhNGF 60 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 60 µg/mL Part A</description>
          </group>
          <group group_id="O6">
            <title>rhNGF 180 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 180 µg/mL Part A</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects Placebo Part A</description>
          </group>
          <group group_id="O8">
            <title>rhNGF 20 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subject
rhNGF 20 µg/mL Part B</description>
          </group>
          <group group_id="O9">
            <title>rhNGF 60 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 60 µg/mL Part B</description>
          </group>
          <group group_id="O10">
            <title>rhNGF 180 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 180 µg/mL Part B</description>
          </group>
          <group group_id="O11">
            <title>Placebo Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
Placebo Part B</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intraocular Pressure (IOP)</title>
          <description>Intraocular pressure was determined using Goldmann applanation tonometry. The study includes Part 0, Part A and Part B. In Part B this endpoint was evaluated at screening and on days 7, 15 (FU).
Follow up (FU) refers to participants' last available assessment.</description>
          <population>Safety population: consisted of all subjects randomised into the study and receiving a dose of study medication.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 7 vs screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="2.0"/>
                    <measurement group_id="O2" value="-1" spread="1.5"/>
                    <measurement group_id="O3" value="-1" spread="2.6"/>
                    <measurement group_id="O4" value="1" spread="1.8"/>
                    <measurement group_id="O5" value="1" spread="3.9"/>
                    <measurement group_id="O6" value="1" spread="1.6"/>
                    <measurement group_id="O7" value="-2" spread="1.8"/>
                    <measurement group_id="O8" value="-1" spread="2.0"/>
                    <measurement group_id="O9" value="0" spread="3"/>
                    <measurement group_id="O10" value="-2" spread="3.7"/>
                    <measurement group_id="O11" value="-2" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15 (FU) vs screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" spread="2.5"/>
                    <measurement group_id="O2" value="1" spread="0.6"/>
                    <measurement group_id="O3" value="-1" spread="1.0"/>
                    <measurement group_id="O4" value="1" spread="2.7"/>
                    <measurement group_id="O5" value="-1" spread="3.3"/>
                    <measurement group_id="O6" value="1" spread="3.2"/>
                    <measurement group_id="O7" value="-2" spread="2.8"/>
                    <measurement group_id="O8" value="0" spread="5.3"/>
                    <measurement group_id="O9" value="-1" spread="3.3"/>
                    <measurement group_id="O10" value="-1" spread="3.1"/>
                    <measurement group_id="O11" value="-3" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Abnormal Findings in Dilated Fundus Ophthalmoscopy</title>
        <description>Dilated fundus ophthalmoscopy (DFO) is used to view the eye's interior, allowing assessment of the retina/macula/choroid, optic nerve head, blood vessels, and other features.
The outcome can be normal or abnormal. The study includes Part 0, Part A and Part B. In Part B this endpoint was evaluated on day 7.</description>
        <time_frame>Part B - Day 7</time_frame>
        <population>Safety population: consisted of all subjects randomised into the study and receiving a dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>rhNGF 0.5 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 0.5 µg/mL Sentinel: one drop administration</description>
          </group>
          <group group_id="O2">
            <title>rhNGF 5 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 5 µg/mL Sentinel</description>
          </group>
          <group group_id="O3">
            <title>rhNGF 20 µg/mL Sentinel</title>
            <description>1 x 35 µL drop 3 subjects rhNGF 20 µg/mL Sentinel</description>
          </group>
          <group group_id="O4">
            <title>rhNGF 60 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 60 µg/mL Part A</description>
          </group>
          <group group_id="O5">
            <title>rhNGF 20 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 20 µg/mL Part A</description>
          </group>
          <group group_id="O6">
            <title>rhNGF 180 µg/mL Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects rhNGF 180 µg/mL Part A</description>
          </group>
          <group group_id="O7">
            <title>Placebo Part A</title>
            <description>3 x 35 µL drops applied at 4 h intervals 6 subjects Placebo Part A</description>
          </group>
          <group group_id="O8">
            <title>rhNGF 20 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subject
rhNGF 20 µg/mL Part B</description>
          </group>
          <group group_id="O9">
            <title>rhNGF 60 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 60 µg/mL Part B</description>
          </group>
          <group group_id="O10">
            <title>rhNGF 180 µg/mL Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 180 µg/mL Part B</description>
          </group>
          <group group_id="O11">
            <title>Placebo Part B</title>
            <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
Placebo Part B</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Abnormal Findings in Dilated Fundus Ophthalmoscopy</title>
          <description>Dilated fundus ophthalmoscopy (DFO) is used to view the eye's interior, allowing assessment of the retina/macula/choroid, optic nerve head, blood vessels, and other features.
The outcome can be normal or abnormal. The study includes Part 0, Part A and Part B. In Part B this endpoint was evaluated on day 7.</description>
          <population>Safety population: consisted of all subjects randomised into the study and receiving a dose of study medication.</population>
          <units>percentage of abnormal findings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="12"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                    <measurement group_id="O3" value="0" spread="0"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                    <measurement group_id="O5" value="0" spread="0"/>
                    <measurement group_id="O6" value="0" spread="0"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                    <measurement group_id="O8" value="0" spread="0"/>
                    <measurement group_id="O9" value="0" spread="0"/>
                    <measurement group_id="O10" value="0" spread="0"/>
                    <measurement group_id="O11" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>rhNGF 0.5 µg/mL Sentinel</title>
          <description>1 x 35 µL drop 3 subjects
rhNGF 0.5 µg/mL Sentinel: one drop administration</description>
        </group>
        <group group_id="E2">
          <title>rhNGF 5 µg/mL Sentinel</title>
          <description>1 x 35 µL drop 3 subjects
rhNGF 5 µg/mL Sentinel</description>
        </group>
        <group group_id="E3">
          <title>rhNGF 20 µg/mL Sentinel</title>
          <description>1 x 35 µL drop 3 subjects
rhNGF 20 µg/mL Sentinel</description>
        </group>
        <group group_id="E4">
          <title>rhNGF 20 µg/mL Part A</title>
          <description>3 x 35 µL drops applied at 4 h intervals 6 subjects
rhNGF 20 µg/mL Part A</description>
        </group>
        <group group_id="E5">
          <title>rhNGF 60 µg/mL Part A</title>
          <description>3 x 35 µL drops applied at 4 h intervals 6 subjects
rhNGF 60 µg/mL Part A</description>
        </group>
        <group group_id="E6">
          <title>rhNGF 180 µg/mL Part A</title>
          <description>3 x 35 µL drops applied at 4 h intervals 6 subjects
rhNGF 180 µg/mL Part A</description>
        </group>
        <group group_id="E7">
          <title>Placebo Part A</title>
          <description>3 x 35 µL drops applied at 4 h intervals 6 subjects
Placebo Part A</description>
        </group>
        <group group_id="E8">
          <title>rhNGF 20 µg/mL Part B</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 12 subject
rhNGF 20 µg/mL Part B</description>
        </group>
        <group group_id="E9">
          <title>rhNGF 60 µg/mL Part B</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 60 µg/mL Part B</description>
        </group>
        <group group_id="E10">
          <title>rhNGF 180 µg/mL Part B</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 9 subjects
rhNGF 180 µg/mL Part B</description>
        </group>
        <group group_id="E11">
          <title>Placebo Part B</title>
          <description>3 x 35 µL drops applied at 4 h intervals per day during 5 consecutive days 10 subjects
Placebo Part B</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="12"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormals sensation in eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eyelid irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Corneal staining</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Orapharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations and caveats area defined.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Flavio Mantelli, MD, PhD</name_or_title>
      <organization>Dompé s.p.a.</organization>
      <phone>+39 0862 3381</phone>
      <email>info@dompe.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

